Ono Pharmaceutical Co., Ltd. Drug Pipeline

Ono Pharmaceutical Co., Ltd. maintains a substantial clinical development portfolio, with 80 registered trials since 2008, of which 35 are currently active. These active programs span from Phase 1 through Phase 3, with 15 trials in Phase 1, 15 in Phase 2, and 5 in Phase 3. The portfolio covers 13 therapeutic areas, but is heavily concentrated in oncology, which accounts for approximately 66% of active programs (23 trials). Within oncology, the leading indications are Non-Hodgkin Lymphoma (7 active trials, including one in Phase 3), Advanced Solid Tumors (3 active trials), Colorectal Cancer (3 active trials), Non-Small Cell Lung Cancer (2 active trials), and Gastric Cancer (2 active trials, including one in Phase 3). Outside of oncology, the central nervous system (CNS) is the next most active area, with 5 ongoing trials. Pain is the only other therapeutic area with an active trial. The concentration in oncology suggests a strategic focus on this area, with Non-Hodgkin Lymphoma and Gastric Cancer representing the most mature assets in the pipeline.